GleamWall
中文EN

GRFS Grifols SA IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1438569 · Reporting currency EUR

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY9.4%
TTM net income YoY270.8%
TTM EPS YoY283.3%
Revenue 3-yr CAGR13.5%
Net income 3-yr CAGR-6.0%

Margins

Gross margin38.7%
Operating margin16.5%
Net margin2.2%
FCF margin9.3%
EBITDA margin22.6%

Returns

ROE2.8%
ROA0.7%
ROIC (approx.)7.1%
Asset turnover0.34x

Leverage & solvency

Liabilities / assets59.8%
Debt / equity0.45x
Current ratio2.66x
Interest coverage1.67x

Cash quality & payout

Operating cash flow / net income5.75x
Accruals ratio-3.5%
Payout ratio0.6%
Capex / revenue3.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: EUR FY20242024-12-31FY20232023-12-31
Income statement
Revenue7.21B6.59B
Cost of revenue4.42B4.11B
Gross profit2.79B2.48B
R&D expense384.04M395.28M
SG&A expense1.26B1.37B
Operating income1.19B782.32M
Interest expense714.76M596.88M
Pretax income444.00M207.02M
Income tax231.19M43.35M
Net income156.92M42.32M
EBITDA1.63B1.23B
EPS (basic)0.230.06
EPS (diluted)0.230.06
Weighted avg. shares (diluted)679.92M677.10M
Balance sheet
Cash & equivalents979.78M529.58M
Receivables835.60M767.26M
Inventory3.56B3.48B
Current assets5.73B6.13B
PP&E, netmay include right-of-use assets (IFRS)3.34B3.25B
Goodwill7.40B6.80B
Intangibles2.93B2.83B
Total assets21.41B20.99B
Current liabilities2.16B2.33B
Short-term debt318.20M674.31M
Long-term debt2.34B3.65B
Total debt2.66B4.32B
Total liabilities12.80B13.48B
Shareholders' equity5.88B5.37B
Net debt1.68B3.79B
Cash flow statement
Operating cash flow902.17M218.69M
Capital expenditure232.54M224.44M
Free cash flow669.63M-5.75M
Investing cash flow886.67M-394.72M
Financing cash flow-1.36B171.49M
Depreciation & amortization437.90M446.42M
Dividends paid962,0000
Share buybacks—0

Free plan shows the latest 2 periods; Pro shows all 10 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.